A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia.

Affiliation

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. [Email]

Abstract

The oral proteasome inhibitor oprozomib has shown preclinical antitumor activity. Here, we report phase Ib/II study results investigating single-agent oprozomib in patients with relapsed multiple myeloma and Waldenström macroglobulinemia.

OUR Recent Articles